Vaginal Drug Delivery Systems for HIV Prevention
- 5 February 2009
- journal article
- review article
- Published by Springer Nature in The AAPS Journal
- Vol. 11 (1) , 78-87
- https://doi.org/10.1208/s12248-009-9082-7
Abstract
Microbicides have become a principal focus for HIV prevention strategies. The successful design of drug delivery systems for vaginal microbicide drug candidates brings with it a multitude of challenges. It is imperative that the chemical and physical characteristics of the drug candidate and its mechanism of action be clearly understood and considered to successfully deliver and target drug candidates efficiently. In addition, an understanding of the dynamic nature of the vaginal environment, the tissue and innate barriers present, as well as patient preferences are critical considerations in the design of effective microbicide products. Although the majority of drug candidates clinically evaluated to date have been delivered using conventional semisolid aqueous-based gel dosage forms, drug delivery system design has recently been extended to include advanced delivery systems such as vaginal rings, quick-dissolve films, and tablets. Ultimately, it may be necessary to develop multiple dosage platforms for a single active agent to provide users with options that can be used within the constraints of their social environment, personal choice, and environmental conditions.Keywords
This publication has 129 references indexed in Scilit:
- Short Communication:Enhancement of HIV Infection by Cellulose SulfateAIDS Research and Human Retroviruses, 2008
- Killing of Neisseria gonorrhoeae, Streptococcus agalactiae (Group B Streptococcus), Haemophilus ducreyi , and Vaginal Lactobacillus by 3- O -Octyl- sn -GlycerolAntimicrobial Agents and Chemotherapy, 2008
- Proteomic Analysis of Human Cervical-Vaginal FluidsJournal of Proteome Research, 2007
- Preclinical Safety Assessments of UC781 Anti-Human Immunodeficiency Virus Topical Microbicide FormulationsAntimicrobial Agents and Chemotherapy, 2007
- Preclinical Testing of Candidate Topical Microbicides for Anti-Human Immunodeficiency Virus Type 1 Activity and Tissue Toxicity in a Human Cervical Explant CultureAntimicrobial Agents and Chemotherapy, 2007
- Proteomic analysis and characterisation of human cervico‐vaginal fluid proteinsAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2007
- Engineered VaginalLactobacillusStrain for Mucosal Delivery of the Human Immunodeficiency Virus Inhibitor Cyanovirin-NAntimicrobial Agents and Chemotherapy, 2006
- Cellulose Acetate 1,2-Benzenedicarboxylate Inhibits Infection by Cell-Free and Cell-Associated Primary HIV-1 IsolatesAIDS Research and Human Retroviruses, 2006
- Effects of Long-Term Use of Nonoxynol-9 on VaginalFloraObstetrics & Gynecology, 2006
- Immunology of the human genital tractCurrent Opinion in Infectious Diseases, 2003